You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Anoro is generally well tolerated1

Please refer to the SmPC for further information on the Anoro Ellipta safety profile prior to prescribing

Support your patients starting on Anoro Ellipta maintenance therapy

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie.
Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Anoro is a registered trademark of the GlaxoSmithKline group of companies.

Innoviva logo

PM-IE-UCV-WCNT-210017 January 2024